Resources

Artemisinin-based combination therapy is considered the gold standard treatment for malaria, but global demand has often outpaced production, and pricing has been volatile. This fact sheet describes the cross-sector partnership PATH formed to develop a new way to produce high-quality, nonseasonal, and affordable artemisinin to supplement the plant-based supply.

This fact sheet provides an overview of PATH's work, global presence, innovation platforms, partners, and funding. It is available in English, French, Russian, and Spanish.

This success story displays positive outcomes of PATH's work in the Democratic Republic of Congo related to the control and treatment of multidrug-resistant tuberculosis (MDR-TB), achieved by introducing the innovative GeneXpert diagnostic machine. This work was made possible with funding from the United States Agency for International Development.

This success story shares two personal stories of multidrug-resistant tuberculosis (MDR-TB) patients who received lifesaving diagnoses and treatment support thanks to the work of PATH in the Democratic Republic of Congo. This work was made possible with generous funding from the United States Agency for International Development.

This success story displays positive outcomes of PATH's work in the Democratic Republic of Congo related to the control and treatment of tuberculosis, achieved through leveraging the strength of the community. This work was made possible with generous funding from the United States Agency for International Development.